Pharmaceuticals
Supply problems force Pfizer to slash COVID-19 vaccine target
2020 production now seen as enough for 25 million people, half of earlier goal
2020 production now seen as enough for 25 million people, half of earlier goal
Emergency use of BioNTech/Pfizer jab authorized ahead of US and EU
Drugmaker says treatment is equally effective across demographic groups
Fast-track approval an option for Pfizer, AstraZeneca or Moderna jabs
Xi made inoculation diplomacy a key part of global strategy
University says some vials in the trial didn't have right concentration of vaccine
Find out who is leading the race among over 200 candidates under development
UK drugmaker promises up to 200m doses by end of year
Takeda alliance focuses on therapy derived from patients' blood
US company close to deal with European Commission, CEO tells German paper
Stay ahead with our exclusives on Asia;
the most dynamic market in the world.
Stay ahead with our exclusives on Asia
Get trusted insights from experts within Asia itself.
Get trusted insights from experts
within Asia itself.
Stay ahead with our exclusives on Asia; the most dynamic market in the world.
Get trusted insights from experts
within Asia itself.
Offer ends January 31st
You need a subscription to...
You need a subscription to:
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our Cookie Policy to learn how you can update your cookie settings.
Accept & Continue Close